WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2016--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into a strategic partnership with the
Milner Therapeutics Institute and Consortium.
The Milner Therapeutics Institute aims to accelerate academic research
by forging collaborative interactions between scientists and the
pharmaceutical industry to deliver better therapies for patients. The
outreach arm of the Institute, the Milner Therapeutics Consortium,
connects academic scientists and institutions in Cambridge, U.K., with
the pharmaceutical industry to develop the therapeutic potential of
their research. The Consortium consists of four major pharmaceutical
companies, Astex, AstraZeneca, GlaxoSmithKline, and Shionogi, along with
three academic centers, University of Cambridge, Babraham Institute, and
Sanger Institute.
“Our partnership with the Milner Therapeutics Institute and Consortium
further enables the collaboration between academics and pharmaceutical
companies as they partner to investigate the therapeutic potential of
their research,” said Emily Hickey, DVM, Ph.D., Corporate Senior Vice
President, Global Discovery Services at Charles River. “Charles River
has had great success partnering with academic consortia in the United
States, and we look forward to the same success in our first major
research collaboration in the United Kingdom.”
Through this partnership, the academic institutions in the Consortium
will have access to Charles River’s early discovery and drug development
resources and services to accelerate their early-stage drug development
processes. Charles River is the first full-service, early-stage contract
research organization (CRO) to partner with the Milner Therapeutics
Institute and Consortium.
“We are excited to welcome Charles River as the newest partner to the
Milner Therapeutics Institute,” said Tony Kouzarides, Founder and
Director of the Milner Therapeutics Institute and Consortium. “Charles
River is uniquely positioned to help guide novel therapies from early
discovery through safety testing. Their scientific expertise and wealth
of industry knowledge will provide significant collaborative
opportunities for the scientists in our program.”
The Milner Therapeutics Consortium was established in 2015 to act as a
“match-making” service between pharmaceutical companies and researchers
in Cambridge. The Consortium brings together the drug development
capability of pharmaceutical companies with the discovery expertise of
academic institutions in Cambridge and has been specifically modeled to
facilitate the speedy exchange of resources and information between
partners through a pre-signed agreement.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
About Milner Therapeutics Consortium
The Milner Therapeutics Consortium consists of four major pharmaceutical
companies, (Astex, AstraZeneca, GlaxoSmithKline and Shionogi) and three
academic centres (University of Cambridge, Babraham Institute and Sanger
Institute). A Consortium agreement is in place to facilitate rapid
exchange of reagents and information between partners in all therapeutic
areas. Pharmaceutical partners set aside funds and use the Consortium
agreement to collaborate with scientists in the academic centres. The
Consortium is the outreach program of the Milner Therapeutics Institute
which is under construction on the Cambridge Biomedical Campus and will
open early in 2018.
The Milner also has an Affiliated partner scheme to enable members of
the Consortium to engage and collaborate with technology or service
providers. Charles River Laboratories will be a key partner in this
endeavor.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160808006139/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com
